JP2022523548A5 - - Google Patents
Info
- Publication number
- JP2022523548A5 JP2022523548A5 JP2021552571A JP2021552571A JP2022523548A5 JP 2022523548 A5 JP2022523548 A5 JP 2022523548A5 JP 2021552571 A JP2021552571 A JP 2021552571A JP 2021552571 A JP2021552571 A JP 2021552571A JP 2022523548 A5 JP2022523548 A5 JP 2022523548A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- therapeutic agent
- weight
- biodegradable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024176400A JP7852008B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176401A JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814198P | 2019-03-05 | 2019-03-05 | |
| US62/814,198 | 2019-03-05 | ||
| PCT/US2020/021136 WO2020181060A1 (en) | 2019-03-05 | 2020-03-05 | Pharmaceutical compositions for treating ocular diseases or disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024176400A Division JP7852008B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176401A Division JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523548A JP2022523548A (ja) | 2022-04-25 |
| JP2022523548A5 true JP2022523548A5 (cg-RX-API-DMAC7.html) | 2023-03-08 |
| JP7570342B2 JP7570342B2 (ja) | 2024-10-21 |
Family
ID=72337143
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552571A Active JP7570342B2 (ja) | 2019-03-05 | 2020-03-05 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176400A Active JP7852008B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176401A Active JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024176400A Active JP7852008B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176401A Active JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12478577B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3934646A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7570342B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN118304422A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020232314C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021017436A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132635A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021010599A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020181060A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3132635A1 (en) | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
| CN115066232B (zh) | 2020-02-06 | 2024-12-10 | 视尔普斯眼科公司 | 用于治疗眼病的组合物和方法 |
| CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
| WO2021207486A1 (en) * | 2020-04-08 | 2021-10-14 | Aerie Pharmaceuticals, Inc. | Treatments |
| BR112023022705A2 (pt) | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| US20240239750A1 (en) | 2021-05-05 | 2024-07-18 | Aerie Pharmaceuticals, Inc. | Pharmaceutical preparation |
| JP2026520094A (ja) | 2023-04-11 | 2026-06-22 | オキュラ セラピューティクス,インコーポレイテッド | アキシチニブ多形ivを含む眼科インプラント |
| IL330178A (en) | 2024-01-03 | 2026-08-01 | LYOTROPIC DELIVERY SYSTEMS Ltd | Topical formulations for delivering active ingredients to the back of the eye |
| AU2025217596A1 (en) | 2024-02-05 | 2026-08-13 | Sun Pharmaceutical Industries Limited | Ophthalmic compositions of tyrosine kinase inhibitors and their uses |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5445130B2 (ja) * | 2006-05-02 | 2014-03-19 | メディバス エルエルシー | 眼の外部または内部への眼科用薬剤の送達法 |
| WO2009130332A1 (en) | 2008-04-25 | 2009-10-29 | Dsm Ip Assets B.V. | Particles comprising polymers with thioester bonds |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| CN107656332B (zh) * | 2010-06-22 | 2021-10-15 | 东洋纺株式会社 | 液晶显示装置、偏振板及偏振片保护膜 |
| BR112013018739A2 (pt) * | 2010-12-29 | 2019-09-24 | Jade Therapeutics Inc | sistema de distribuição de medicamento ocular |
| US20140179802A1 (en) * | 2011-05-02 | 2014-06-26 | Dsm Ip Assets B.V. | Fiber comprising a biodegradable polymer |
| WO2012150255A1 (en) * | 2011-05-02 | 2012-11-08 | Dsm Ip Assets B.V. | Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology |
| HK1205461A1 (zh) * | 2012-02-22 | 2015-12-18 | Trustees Of Tufts College | 用於眼部传输治疗剂的组合物和方法 |
| WO2014053542A1 (en) | 2012-10-02 | 2014-04-10 | Dsm Ip Assets B.V. | Drug delivery composition comprising proteins and biodegradable polyesteramides |
| JP6303199B2 (ja) | 2012-10-24 | 2018-04-04 | ディーエスエム アイピー アセッツ ビー.ブイ. | 薬物送達のためのポリエステルアミドコポリマーを含む繊維 |
| EP2956096A1 (en) * | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| WO2015126477A1 (en) | 2013-11-08 | 2015-08-27 | Tyrx, Inc. | Polymeric drug delivery system for treating surgical complications |
| US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| EP3082761A2 (en) * | 2013-12-20 | 2016-10-26 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
| US9931306B2 (en) | 2014-09-06 | 2018-04-03 | Integral Biosystems Llc | Methods and biocompatible compositions to achieve sustained drug release in the eye |
| CA2969171C (en) * | 2014-12-18 | 2023-12-12 | Dsm Ip Assets B.V. | Drug delivery system for delivery of acid sensitive drugs |
| CN115337254A (zh) | 2015-07-23 | 2022-11-15 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| WO2017120600A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Compositions and methods of treating wet age-related macular degeneration |
| US20180117148A1 (en) * | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| EP3570888A1 (en) * | 2017-03-03 | 2019-11-27 | MacRegen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| CA3132635A1 (en) | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
-
2020
- 2020-03-05 CA CA3132635A patent/CA3132635A1/en active Pending
- 2020-03-05 CN CN202410368231.1A patent/CN118304422A/zh active Pending
- 2020-03-05 WO PCT/US2020/021136 patent/WO2020181060A1/en not_active Ceased
- 2020-03-05 AU AU2020232314A patent/AU2020232314C1/en active Active
- 2020-03-05 JP JP2021552571A patent/JP7570342B2/ja active Active
- 2020-03-05 CN CN202410368463.7A patent/CN118286445A/zh active Pending
- 2020-03-05 CN CN202080033265.5A patent/CN113784727B/zh active Active
- 2020-03-05 BR BR112021017436A patent/BR112021017436A2/pt unknown
- 2020-03-05 US US16/810,149 patent/US12478577B2/en active Active
- 2020-03-05 EP EP20766052.3A patent/EP3934646A4/en active Pending
- 2020-03-05 MX MX2021010599A patent/MX2021010599A/es unknown
-
2021
- 2021-09-02 MX MX2025002265A patent/MX2025002265A/es unknown
-
2024
- 2024-10-08 JP JP2024176400A patent/JP7852008B2/ja active Active
- 2024-10-08 JP JP2024176401A patent/JP7838047B2/ja active Active
-
2025
- 2025-10-10 US US19/355,788 patent/US20260034056A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007248143B2 (en) | A sustained-release intraocular implant comprising a vasoactive agent | |
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| CA2653902C (en) | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye | |
| CN104185472B (zh) | 4‑孕甾烯‑11β‑17‑21‑三醇‑3,20‑二酮衍生物的药物组合物和使用方法 | |
| BR112012018134B1 (pt) | Uso de um agente terapêutico e implante de liberação sustentada biodegradável para tratar uma condição ocular | |
| BRPI0613401B1 (pt) | Composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior | |
| BRPI0617414A2 (pt) | mÉtodo para tratamento de formas primÁrias e secundÁrias de glaucoma | |
| JP2020121985A5 (cg-RX-API-DMAC7.html) | ||
| JP6752276B2 (ja) | 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物 | |
| JP2025004161A (ja) | 眼の疾患又は障害を治療するための医薬組成物 | |
| JP2015506983A5 (cg-RX-API-DMAC7.html) | ||
| JP2019524679A5 (cg-RX-API-DMAC7.html) | ||
| US20060154910A1 (en) | Use of steroids to treat ocular disorders | |
| JP7571037B2 (ja) | 眼表面疼痛を治療する方法 | |
| US10350223B2 (en) | Compositions and methods for treating ocular diseases | |
| CN100431544C (zh) | 用于治疗病理性眼血管生成的糖皮质激素制剂 | |
| JP2016050181A (ja) | 血管炎治療剤 | |
| US20250387410A1 (en) | Treatment of anti-vegf refractory ophthalmic retinal eye conditions | |
| US20090181933A1 (en) | Use of steroids to treat persons suffering from ocular disorders | |
| JP2025507416A5 (cg-RX-API-DMAC7.html) | ||
| EP1781301A2 (en) | Angiostatic agents for controlling choroidal neovascularisation after ocular surgery or trauma | |
| Misra et al. | Comparative evaluation of the antiinflammatory effect of topical 0.1% dexamethasone sodium and topical 1% prednisolone acetate eye drops after small incision cataract surgery in Indian eyes | |
| PT2319517E (pt) | Utilização de pró-fármacos para administração ocular por via intra-vítrea |